The race to produce the first CAR-T, a technology capable of reprograming a cancer patient's white blood cells to kill tumor cells, has reached its next phase, thanks to Novartis. In Forbes, Samuele Butera, the Global Business Leader for Cell & Gene Therapies at Novartis, explains the company’s work in fighting cancer within the body.
After announcing the company had completed the application for the use of CAR-T in children with acute lymphoblastic leukemia, the company is currently waiting for a response from the Food and Drug Administration. Novartis’ application comes before that from Kite Pharmaceuticals, who announced its intention to apply in Dec. 2016.
Read the full story by clicking below:
Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.